A new study published in the Journal of Clinical and Aesthetic Dermatology demonstrated that a majority of patients with acne vulgaris are aware of and concerned about the impact on antibiotic resistance. The study also noted that there were gaps in patient knowledge--specifically regarding topical treatments. In a statement, lead author and SBS faculty member, James Del Rosso, M.D.shared: “Most of the respondents were not aware of antibiotic-free treatment options, but the vast majority were open to using an effective, antibiotic-free treatment for acne vulgaris on themselves or their children.”

 

The U.S. Food and Drug Administration has recently granted Foamix Pharmaceuticals Ltd. approval of its  novel (minocycline) topical foam, 4%. AMZEEQ. Formerly known as FMX101, the product is indicated for the treatment of inflammatory lesions of non-nodule moderate to severe vulgaris in adults and pediatric patients 9 years of age and older and is the first topical minocycline to be approved by the FDA for any condition. The FDA approval is supported by data from three Phase 3 clinical trials in 2,418 patients of 9 years of age or older.

 

The American Society for Dermatology Surgery released survey results demonstrating the numbers of procedures completed by dermatological surgeons in 2018. Of the most than 12.5 million procedures performed, skin cancer treatments, energy-based procedures, injectable neuromodulators, and injectable soft tissue fillers stood at the top of the list. The results found that skin cancer procedures ranked with the highest numbers, with over 3.5 skin cancer treatments performed, 3.3 of which were for non-melanoma skin cancers.

 

Meet Dr. Seemal R. Desai: a Diplomate of the American Board of Dermatology, and a Board Certified Dermatologist. After receiving his medical degree at Morehouse School of Medicine in Atlanta, Georgia, Dr. Desai completed his medical internship in Internal Medicine. He then went on to complete his residency at The University of Alabama at Birmingham, and served as Chief Resident for the Department of Dermatology. Among various roles, Dr. Desai is the current President of the Skin of Color Society and is the only dermatologist appointed to serve on the US Food & Drug Administration, Pharmacy Compounding Advisory Committee (PCAC).

Researchers searching for more efficacious methods to treat hypopigmented scars utilized an improved form of microdermal grafting to treat a cohort of patients with white scars in a recent study published in the Aesthetic Surgery Journal.